BRIEF published on 12/29/2025 at 08:05, 13 days 11 hours ago GenSight Biologics Completes €2.9 Million Fundraising Shareholders Fundraising Gene Therapy Retinal Diseases Compassionate Use
PRESS RELEASE published on 12/29/2025 at 08:00, 13 days 11 hours ago Inside Information / Other news releases GenSight Biologics successfully raises nearly €2.9 million to fund gene therapies for retinal neurodegenerative diseases, plans to use proceeds for development and operational needs through 2026 Fundraising Proceeds GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 12/22/2025 at 07:05, 20 days 12 hours ago Issuance of a compassionate access authorization for GS010/LUMEVOQ® Gene Therapy GenSight Biologics NOHL ANSM Compassionate Access
BRIEF published on 12/22/2025 at 07:05, 20 days 12 hours ago GenSight Biologics Receives Compassionate Use Authorization for GS010/LUMEVOQ® in France Gene Therapy Rare Diseases Compassionate Use LHON Treatment ANSM Approval
PRESS RELEASE published on 12/22/2025 at 07:00, 20 days 12 hours ago Inside Information / Other news releases GenSight Biologics receives Compassionate Use Authorization in France for GS010/LUMEVOQ® gene therapy indicated for ND4-LHON treatment France GenSight Biologics GS010/LUMEVOQ® Compassionate Use Authorization ND4-LHON
BRIEF published on 11/13/2025 at 18:02, 1 month 28 days ago Heights Capital Management crosses thresholds Convertible Bonds Crossing Thresholds Shares And Voting Rights GenSight Biologics Heights Capital
BRIEF published on 10/30/2025 at 07:35, 2 months 12 days ago GenSight Biologics: Green light for compassionate treatment in the United States FDA GenSight Biologics NOHL Compassionate Access GS010/LUMEVOQ®
BRIEF published on 09/29/2025 at 23:05, 3 months 11 days ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 3 months 11 days ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 21:48, 3 months 11 days ago rapport financier semestriel 2025
Published on 01/10/2026 at 05:10, 1 day 14 hours ago Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 19 hours ago Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 1 day 20 hours ago Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 1 day 20 hours ago Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction
Published on 01/10/2026 at 21:25, 22 hours 27 minutes ago CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 6 hours ago SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 1 day 21 hours ago Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 1 hour ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:19, 2 days 1 hour ago EQS-Adhoc: BayWa AG: Change in the Board of Management of BayWa AG
Published on 01/09/2026 at 18:30, 2 days 1 hour ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 2 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 2 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 2 days 22 hours ago Biannual report on SEB S.A.’S liquidity agreement
